KinasePro

Kinase Chemistry – Just a year and a half behind the times.

Archive for August 9th, 2007

The Thursday List

Posted by kinasepro on August 9, 2007

WO/2007/90141 Raf GSK
WO/2007/89768 Jak2 Exelixis
WO/2007/88014 p38 Roche
WO/2007/89646 p38 Array
WO/2007/89192 Gsk3 AstraZeneca
WO/2007/89191 Gsk3 AstraZeneca

US20070185152 AKT GSK
US20070185140 Cdk Sanofi-Aventis
US20070185139 Egf J&J
US20070185133 plk1 Amgen
US20070185125 Tec Vertex
US20070185013 Chk1 ICOS
US20070185081 Egf BI
US20070185091 Egf BI
US20070185098 Flt3, KDR, Tie2, and p38 Locus
US20070185104 GSK3 ARS
US20070185111 Aurora Amgen
US20070185112 p38 Scios
US20070185123 HSC
US20070185134 cdk cyclacel
US20070185143 Aurora Nerviano
US20070185175 p38 BMS
US20070185171 vegf Amgen

Posted in Application List | 1 Comment »

LS-104

Posted by kinasepro on August 9, 2007

The news today is that LS-104 is in Ph1 and now owned by Aegera from Lymphosign who in turn licsensed it from HSC. Their portfolio of patent applications suggests the compound is likely a tyrphostin derivative.

LS104 is a novel small molecule tyrosine kinase inhibitor of therapeutically significant kinases including Jak2 and Bcr-Abl…In contrast to marketed kinase inhibitor drugs, LS104 inhibits its targets in a non-ATP-competitive manner

N#C/C(C(NCC1=CC=C(O)C(O)=C1)=O)=C\C=C\C2=CC(OC)=C(O)C(OC)=C2

WO/2005/092904

I don’ t know about you but I needed a history lesson to get a handle on these

Posted in bcr abl, biotech, JAK | 2 Comments »